Leukemia, Myeloid, Acute: all 3,035 studies

Page 18 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.

• Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)CompletedNCT04942730Phase 2
• A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological MalignanciesTerminatedNCT04937166Phase 1
• Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)TerminatedNCT04920188
• Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid LeukemiaCompletedNCT04915612Phase 1
• Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic SyndromeTerminatedNCT04912063Phase 1
• Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile NeutropeniaCompletedNCT04910698
• Feasibility Pilot Exploring Variability in Biomarkers and PROs in AMLCompletedNCT04908852
• Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 MutationsStatus unknownNCT04906031Phase 2
• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
• Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.Status unknownNCT04904237Phase 2
• Acquired Pyruvate Kinase Deficiency In Clonal Myeloid NeoplasmsCompletedNCT04902833
• Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaActive, not recruitingNCT04898894Phase 1
• A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid LeukemiaWithdrawnNCT04896112Phase 1
• Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDSWithdrawnNCT04893915Phase 2
• FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesActive, not recruitingNCT04891757Phase 1
• A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)CompletedNCT04887857Phase 1
• Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT04886206Phase 1
• Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid LeukemiaCompletedNCT04885127Not applicable
• Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)Status unknownNCT04884984Phase 1/2
• A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow TransplantActive, not recruitingNCT04872595Phase 2
• Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid LeukemiaStatus unknownNCT04867928Phase 2
• Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic SyndromesActive, not recruitingNCT04861207Phase 2
• Study of Periodontitis and Blood Stream Infection in AML Patients Receiving ChemotherapyTerminatedNCT04858594
• Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDSTerminatedNCT04849910Phase 1/2
• Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AMLStatus unknownNCT04842370Phase 1
• Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML PatientsCompletedNCT04839341Phase 1
• Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04835519Phase 1/2
• BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDSCompletedNCT04827719Phase 2
• A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)CompletedNCT04827069Phase 1
• Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)CompletedNCT04826523
• A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive ChemotherapyStatus unknownNCT04824924Phase 2
• A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04822766Not applicable
• Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid LeukemiaCompletedNCT04813263
• A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous LeukemiaStatus unknownNCT04806659Phase 1
• Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLActive, not recruitingNCT04801797Phase 2
• Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT04789655Phase 1
• Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AMLCompletedNCT04788420
• Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic LeukemiaCompletedNCT04774744Not applicable
• Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxActive, not recruitingNCT04763928Phase 2
• A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)TerminatedNCT04755244Phase 1
• Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk FeaturesStatus unknownNCT04752527Phase 2
• A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive TherapyTerminatedNCT04748848Phase 1
• Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.Status unknownNCT04747002Phase 2
• Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT04746235Phase 2
• A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDSStatus unknownNCT04743115Phase 1
• Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid LeukemiaCompletedNCT04742101Phase 1/2
• PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AMLStatus unknownNCT04722952Phase 3
• Safety and Early Efficacy Study of TBX-2400 in Patients With AML or MyelofibrosisStatus unknownNCT04709458Phase 1
• Prognostic Value of CD318 in AML at Assiut University Hospital.Status unknownNCT04708444
• VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)TerminatedNCT04702425Phase 1
• TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid LeukemiaStatus unknownNCT04692948Not applicable
• A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) MutationCompletedNCT04691648
• Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldCompletedNCT04687761Phase 1/2
• Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT04687657Phase 1
• Risk-adapted Therapy for Primary Acute Myeloid LeukemiaCompletedNCT04687098Phase 2
• Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid LeukemiaCompletedNCT04679285
• Flotetuzumab Expanded Access ProgramNo longer availableNCT04678466
• CD123 Redirected T Cells for AML in Pediatric SubjectsTerminatedNCT04678336Phase 1
• A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.Active, not recruitingNCT04671693Not applicable
• PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCTCompletedNCT04669210Phase 2
• TL-895 and KRT-232 Study in Acute Myeloid LeukemiaActive, not recruitingNCT04669067Phase 1/2
• CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDSActive, not recruitingNCT04668885Phase 2
• Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)CompletedNCT04666649Phase 1
• Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)Active, not recruitingNCT04657081Phase 1/2
• Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnNCT04655391Phase 1
• Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid LeukemiaCompletedNCT04641910
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsTerminatedNCT04637009Phase 1
• Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme TestCompletedNCT04635384
• A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid LeukemiaStatus unknownNCT04632316Phase 1/2
• IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT04628338Early Phase 1
• Aerobic Versus Resistive Training on Functional Capacity in Acute Myeloid LeukemiaCompletedNCT04617145Not applicable
• FT538 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04614636Phase 1
• A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04609826Phase 1
• Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsActive, not recruitingNCT04603001Phase 1
• Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96CompletedNCT04589728
• A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.CompletedNCT04580121Phase 1
• Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)CompletedNCT04547062Phase 1
• Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive ChemotherapyStatus unknownNCT04541277Phase 2
• Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST StudyActive, not recruitingNCT04537871
• Diagnosis and Treatment of Periodontal Disease in Patients With AMLWithdrawnNCT04530695Not applicable
• Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
• IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCTCompletedNCT04522895Phase 2
• TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid LeukemiaCompletedNCT04518345Early Phase 1
• Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid LeukemiaCompletedNCT04512105Phase 1
• Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantTerminatedNCT04511130Phase 2
• A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)CompletedNCT04509622Phase 3
• Phase 1 First in Human Study of ZN-d5 as a Single AgentCompletedNCT04500587Phase 1
• Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnNCT04493099Phase 1/2
• Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AMLStatus unknownNCT04490707Phase 3
• Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid LeukemiaSuspendedNCT04485052Phase 1/2
• Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDSActive, not recruitingNCT04482894Not applicable
• A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSTerminatedNCT04477291Phase 1
• Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCTActive, not recruitingNCT04476199Phase 2
• Haplo Peripheral Blood Sct In GVHD PreventionCompletedNCT04473911Phase 1
• Role of Adrenomedullin in Leukemic Endosteal/Vascular NichesActive, not recruitingNCT04460963Not applicable
• Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive ChemotherapyStatus unknownNCT04454580
• Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19CompletedNCT04452604
• ObServatory Children Acute RElated Therapy LeukemiaStatus unknownNCT04450784
• Molecular Diagnostic Platform for AMLStatus unknownNCT04446741
• Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic LeukemiaCompletedNCT04446052Phase 3

← Leukemia, Myeloid, Acute overview